
Noetik is an AI-native biotechnology company focused on revolutionizing cancer immunotherapy discovery and development. By combining self-supervised learning with the industrial-scale generation of human multimodal data, Noetik aims to create foundation models for cell and tissue biology that drive therapeutic innovation. Their approach addresses the limitations of reductionism in understanding complex tumor-immune interactions, leveraging machine learning to add this complexity back into drug discovery. The company is building towards a future of precision immunotherapies that are patient-centric, aiming to develop treatments that were previously unattainable through traditional methods. Their team comprises doctors, scientists, engineers, and machine learning researchers united by a vision to impact patient lives.

Noetik is an AI-native biotechnology company focused on revolutionizing cancer immunotherapy discovery and development. By combining self-supervised learning with the industrial-scale generation of human multimodal data, Noetik aims to create foundation models for cell and tissue biology that drive therapeutic innovation. Their approach addresses the limitations of reductionism in understanding complex tumor-immune interactions, leveraging machine learning to add this complexity back into drug discovery. The company is building towards a future of precision immunotherapies that are patient-centric, aiming to develop treatments that were previously unattainable through traditional methods. Their team comprises doctors, scientists, engineers, and machine learning researchers united by a vision to impact patient lives.
Focus: AI-native biotech building foundation models and high-throughput spatial-biology platforms for precision cancer immunotherapy
Proprietary platforms: OCTO (foundation model / virtual cell modeling) and Perturb-map (high-throughput in vivo screening)
Founders: Jacob Rinaldi and Ron W. Alfa
Founded: 2022
Total funding (reported): USD 55,000,000
Headquarters (city): South San Francisco
Cancer immunotherapy discovery and development; modeling complex tumor–immune interactions from multimodal spatial biology data.
2022
Biotechnology
Crunchbase lists a Grant as a recent funding event with AWS noted among recent investors.
“Investor syndicate includes DCVC and Polaris Partners as notable leads in seed/Series A activity; additional investors include Zetta Venture Partners, Khosla Ventures, Linearis Ventures, Amazon Web Services, Polaris Partners, DCVC and others.”